|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Darinaparsin>> Market Analysis Reports |
Market Analysis Reports of Darinaparsin |
|
ZIOPHARM Oncology, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... includes palifosfamide (Zymafos, ZIO-201), darinaparsin (Zinapar, ZIO-101), and ... II trials for the IV form of darinaparsin and reported favorable Phase II ... . Product Candidates ZIO-101, Darinaparsin, Zinapar Darinaparsin is a novel anti-mitochondrial agent ... Solasia Pharma KK Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral ... Peripheral T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2023 This report can be delivered to the clients within 24 Hours DelveInsight’s ‘Peripheral T-Cell Lymphoma (PTCL) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025’ report provides provides the comprehensive insights on the ... T cell lymphoma - Pipeline Insight, 2021 ... is being developed by Soligenix. SP-02: Solasia Pharma SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organic ... cancers. In a Phase II study in the U.S. Intravenous darinaparsin demonstrated evidence of clinical activity in malignant ... |